



CASE 4-30096/A/CPA

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV3 36720 339US
Express Mail Label Number

3/26/2004
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1624

ZIMMERMANN ET AL.

Examiner: Emily Bernhardt

APPLICATION NO: 09/463,097

FILED: JANUARY 18, 2000

FOR: CRYSTAL MODIFICATION OF A N-PHENYL-2-PYRIMIDINEAMINE
DERIVATIVE, PROCESSES FOR ITS MANUFACTURE AND ITS
USE

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed simultaneously with the filing of the above-referenced continued prosecution application. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.


In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form PTO-1449.

Copies of these references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form.

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 430
East Hanover, NJ 07936-1080
(862) 778-7824


George R. Dohmann
Attorney for Applicants
Reg. No. 33,593

Date: 3/26/2004

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

4-30096/A/CPA

APPLICATION NO.

09/463,097

APPLICANT

ZIMMERMANN ET AL.

FILING DATE

JANUARY 18, 2000

Group
1624

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA					
	AB					
	AC					
	AD					
	AE					
	AF					
	AG					
	AH					
	AI					
	AJ					
	AK					
	AL					

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES NO	
	AM					<input type="checkbox"/>	<input type="checkbox"/>
	AN					<input type="checkbox"/>	<input type="checkbox"/>
	AO					<input type="checkbox"/>	<input type="checkbox"/>
	AP					<input type="checkbox"/>	<input type="checkbox"/>
	AQ					<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AR	Zimmermann, et al., Potent and Selective Inhibitors of the Abl-Kinase: Phenylaminopyrimidine (PAP) Derivatives, Bioorganic & Medicinal Chemistry Letters, Vol. 7, No. 2, pp. 187-192 (1997)
AS	Elisabeth Buchdunger, et al., Inhibition of the Abl Protein-Tyrosine Kinase in Vitro and in Vivo by a 2-Phenylaminopyrimidine Derivatives, Cancer Research, pp. 100-104, January 1, 1996
AT	

EXAMINER

DATE CONSIDERED

*EXAMINER Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.